Illumina (NASDAQ:ILMN) Director Sells 95,000 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 95,000 shares of Illumina stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $203.29, for a total transaction of $19,312,550.00. Following the completion of the sale, the director owned 1,994,425 shares in the company, valued at approximately $405,446,658.25. This trade represents a 4.55% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Illumina Stock Up 2.9%

Shares of ILMN stock traded up $6.16 during mid-day trading on Friday, reaching $219.40. 1,917,079 shares of the company’s stock traded hands, compared to its average volume of 2,061,622. The company’s 50-day moving average price is $188.01 and its 200-day moving average price is $152.44. The company has a market cap of $33.13 billion, a P/E ratio of 40.93, a P/E/G ratio of 3.00 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 12 month low of $88.00 and a 12 month high of $220.43.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.08. The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period in the previous year, the company earned $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, equities analysts expect that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on the company. Barclays lifted their price objective on Illumina from $145.00 to $160.00 and gave the company an “underweight” rating in a research report on Friday, July 31st. Weiss Ratings raised shares of Illumina from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, June 3rd. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a “hold” rating in a research report on Wednesday, August 5th. Canaccord Genuity Group raised their price objective on shares of Illumina from $190.00 to $205.00 and gave the company a “hold” rating in a research report on Monday, August 3rd. Finally, Guggenheim lifted their target price on shares of Illumina from $200.00 to $226.00 and gave the company a “buy” rating in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, Illumina currently has a consensus rating of “Hold” and an average target price of $188.40.

Institutional Trading of Illumina

Several hedge funds have recently made changes to their positions in the business. Fiduciary Financial Advisors bought a new stake in shares of Illumina in the 2nd quarter valued at approximately $26,000. Keating Financial Advisory Services Inc. bought a new position in shares of Illumina during the 2nd quarter valued at approximately $32,000. Rakuten Securities Inc. purchased a new stake in Illumina during the 2nd quarter valued at $33,000. Elyxium Wealth LLC purchased a new stake in Illumina during the 4th quarter valued at $25,000. Finally, TD Waterhouse Canada Inc. bought a new stake in Illumina in the fourth quarter worth $26,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.